New drug cocktail aims to tackle tough breast cancer

NCT ID NCT06042894

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests two experimental drugs, SI-B003 and BL-B01D1, in people with advanced HER2-negative breast cancer that has not responded to standard treatments. The study will see if the drugs can shrink tumors and determine the best dose. About 58 participants will receive either SI-B003 alone or a combination of both drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SI-B003 (an immunotherapy drug) and BL-B01D1 (a targeted drug that delivers chemotherapy directly to cancer cells)
What this could lead to
If successful, this could offer a new treatment option for people with advanced HER2-negative breast cancer who have run out of standard therapies.
What could go wrong
This is an early phase II trial with only 58 participants, so results may not apply to everyone. The combination therapy may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.